SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in
adults with COVID-19 who do not need to be in the hospital but who are at high risk for
progression to severe disease. Eligible subjects will be randomly assigned (by chance) to
receive BEM or matching placebo orally for 5 days. Co-administration of locally available
standard of care (SOC) is allowed. The total duration of the study is 60 days.